Targeting tumor angiogenesis has been approached through two methods: monoclonal antibodies that block VEGF–VEGFR binding, and small molecule TKIs that inhibit the downstream VEGFR mediated signaling [1]. This evidence concerns the gene KDR and neoplasm.